Prevalence of neuromyelitis optica spectrum disorder in the United States.

ABSTRACT:

Background

Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.

Objective

The objective of this study was to determine the 2022 US prevalence of NMOSD.

Methods

We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.

Results

There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Preva

SUBMITTER: Briggs FB 

PROVIDER: S-EPMC11282172 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature